Clinical Trial Update: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma [Phase 1]

View source ↗

Summary

This is an open-label, dose-escalation Phase 1 trial of HMPL-523 in patients with Non-Hodgkin lymphoma. The study has been terminated and results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• HMPL-523

Snippet

Sponsor: Hutchmed | Conditions: Non Hodgkin Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2026-02-18